Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484162 | 0.88 | ALDH1A1 (0.49) | FPR2LMNAPOLBMEN1KMT2A | |
| SCHEMBL7216770 | 0.88 | FFAR1 (0.53) | CNR2KLK7FPR2LMNAPOLB | |
| SCHEMBL5183992 | 0.87 | ATM (0.55) | TDP1KLK7SMN1; SMN2POLBMEN1 | |
| SCHEMBL1521950 | 0.87 | CA1 (0.50) | CNR2MEN1KMT2AATMALDH1A1 | |
| SCHEMBL11650986 | 0.86 | FFAR1 (0.47) | SMN1; SMN2LMNAPOLBMEN1KMT2A | |
| SCHEMBL9065846 | 0.84 | ALDH1A1 (0.46) | CNR2KLK7LMNAPOLBCNR1 | |
| SCHEMBL4438089 | 0.83 | GAA (0.53) | MEN1KMT2AATMALDH1A1 | |
| SCHEMBL7278760 | 0.83 | GAA (0.53) | MEN1KMT2AATMALDH1A1 | |
| SCHEMBL9626243 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL9054330 | 0.79 | HCAR2 (0.47) | LMNACNR1HPGDALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003066633-A1 | NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216575-A1 | Novel pyranosyl cytosines: pharmaceutical formulations and methods | RNGTT, NOP2, RNMT | CNR2 4395/4885TDP1 520/4885KLK7 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.